Initial Presentations from Santa Monica Targeted Therapies

[Guest LCSC Info]

Initial Presentations from Santa Monica Targeted Therapies Discussion: Drs. Rudin and Shaw

http://blog.lungevity.org/2012/04/20/in ... -and-shaw/

April 20th, 2012 - by Dr. Jack West

Here is the introduction and first two presentations from our special webinar at the Santa Monica “Targeted Therapies in Lung Cancer” meeting several weeks ago. I was honored to be joined there by four guest faculty members who are true experts in the field — Dr. Charles Rudin from Johns Hopkins University in Baltimore, Dr. Alice Shaw from Massachusetts General Hospital in Boston, Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, and Dr. Glen Goss from the University of Ottawa. We discussed the complexity of this evolving field and where our perspectives converge and differ.

Immediately below are the audio and video versions of the first podcast, with introductory comments and then a presentation by Dr. Rudin on the Lung Cancer Mutation Consortium. You’ll also find links to the transcript and figures.

(Click on the link above to view the podcast links)

SM Molecular Markers Pt 1 Intro and Rudin on LCMC Video Podcast

SM Molecular Markers Pt 1 Intro and Rudin on LCMC Audio Podcast

SM Molecular Markers Pt 1 Intro and Rudin on LCMC Transcript

SM Molecular Markers Pt 1 Intro and Rudin on LCMC Figures

We then had some additional discussion based on some of the implications from that work.

In a second podcast, Dr. Alice Shaw presented data from their experience of doing broad molecular profiling their patients at Massachusetts General Hospital and some of the results broken down by clinical and pathologic characteristics of the cancers. Here are the video and audio versions of her podcast, along with with the transcript and figures:

(Click on the link above to view the podcast links)

SM Molecular Markers Pt 2 Shaw on Markers by Clin Factors Video Podcast

SM Molecular Markers Pt 2 Shaw on Markers by Clin Factors Audio Podcast

SM Molecular Markers Pt 2 Shaw on Markers by Clin Factors Transcript

SM Molecular Markers Pt 2 Shaw on Markers by Clin Factors Figs

Personally, I found her presentation especially interesting, notably for identifying some potentially fruitful targets in squamous cell carcinoma, which we all know is an underserved cancer population that is quite overdue for novel therapies.

We’ll then turn in the next couple of podcasts to further panel discussion about the appeal and challenges of more widespread molecular testing, and Dr. Spigel will address the issues with incorporating these markers into new clinical trials.